top of page

Immune checkpoint inhibitor Opdivo


About Opdivo

Opdivo, also known as an immune checkpoint inhibitor, can have an effect on non-small cell lung cancer that cannot be surgically removed or progresses and recurs. It is a new drug in recent years. Cancer treatment drugs include anticancer drugs, molecular target drugs, hormonal drugs, etc., but immune checkpoint inhibitors have a different mechanism of action from these drugs, so they have attracted attention, and countries around the world are actively developing such drugs.

immune checkpoint inhibitors

Immune cells themselves have the ability to attack and eliminate foreign substances in the body. In the early stages, when the number of cancer cells is low, immune cells are usually able to eliminate cancer cells. However, overactivation of immune cells can trigger an autoimmune response that attacks their own normal cells, so immune cells have molecules on their surface that suppress the immune response, called immune checkpoints, and some cancer cells have Molecules that act on immune checkpoints to prevent an immune response from occurring. The role of immune checkpoint inhibitors, therefore, is to block the function of these molecules, awakening the primordial ability of immune cells to attack cancer cells. Based on the results of multiple clinical trials, immune checkpoint inhibitors have been shown to be effective against a variety of cancers.

Helps facilitate the attack on cancer cells by releasing the immune suppression of T cells

When Opdivo enters the blood, it will connect with PD-1 on T cells, thereby blocking the combination with cancer cells and releasing the suppression of immune function. This action allows T cells to attack cancer cells without interference.


Side Effects Confirmed by Opdivo in Japan

  • Interstitial lung disease (pneumonia, lung infiltrates, lung injury, etc.)

  • Myasthenia gravis, myocarditis, myositis, rhabdomyolysis, or comorbidities of these conditions

  • Colitis, enteritis, severe diarrhea

  • type 1 diabetes

  • Severe blood disorders (immune thrombocytopenic purpura, hemolytic anemia, agranulocytosis, etc.)

  • Pulmonary insufficiency, liver dysfunction, hepatitis, sclerosing cholangitis

  • Thyroid dysfunction

  • pituitary dysfunction

  • nervous disorder

  • kidney dysfunction

  • adrenal dysfunction

  • encephalitis

  • severe skin disorder

  • venous thromboembolism

  • hemophagocytosis syndromegroup

  • tuberculosis

  • pancreatitis


For these side effects, corresponding management and treatment should be carried out according to the specific conditions of the patients. if inOpdivoAny discomfort or side effects during use should be reported to a doctor immediately for proper treatment and treatment.

Remarks: Taiwan has aboutOpdivoReferences for side effects

Symptoms of Opdivo Adaptation in Japan

  • malignant melanoma

  • Unresectable, progressive or recurrent non-small cell lung cancer

  • unresectable or metastatic renal cell carcinoma

  • relapsed or refractory classical Hodgkin lymphoma

  • recurrent or metastatic head and neck cancer

  • Progressive, recurrent gastric cancer that has worsened and is unresectable after chemotherapy

  • After chemotherapy, worsening andcan'tprogress of resection,recurrent pleural mesothelioma

  • After chemotherapy, worsening andcan'tprogress of resection,Recurrent colorectal cancer with MSI-High

  • After chemotherapy, worsening andcan'tprogress of resection,recurrent esophageal cancer

Remarks: Taiwan has abouOpdivo References for Adaptive Symptoms

In some cases, the Hiroi Clinic will use a lower dose of Opdivo about 20mg, and the general dosage in Japan is 240mg. There are also some cases where the use of lower doses has shown effects and can suppress the occurrence of side effects. The clinic recommends adjusting according to each patient's situation and closely observing the efficacy.


Opdivo plus Yervoy therapy

About Opdivo and Yervoy combination therapy is an approach that combines two different immune checkpoint inhibitors for treatment. They have the effect of relieving immunosuppression on T cells. Opdivo acts on "PD-1" on T cells, and Yervoy acts on "CTLA-4". Each of them binds to the antigen of T cells, blocks the inhibitory signal, and relieves immune suppression. This way, the T cells are able to attack the cancer cells again without interference. Opdivo and Yervoy  combination therapy further enhances the attack power against cancer cells by combining two immune checkpoint inhibitors to achieve more effective treatment.

About Yervoy

Yervoy  is a drug that binds CTLA-4, blocking its interaction with certain substances. It has been reported that when CTLA-4 is blocked, it can promote the activation and proliferation of T cells.


Yervoy adaptation symptoms

unresectable malignant melanoma

incurable or metastatic renal cell carcinoma

After chemotherapy,Unresectable colorectal cancer with MSI-High

Unresectable progressive, recurrent non-small cell lung cancer

Unresectable progressive,recurrent malignant pleural mesothelioma

Remarks: Taiwan has aboutYervoyReferences for Adaptive Symptoms

Clinic introduction

Comfortable and spacious clinic interior

スクリーンショット 2023-07-07 17.22.05.png

Dean's introduction




1990 Graduated from Aichi Medical University

worked in

First Department of Surgery, Aichi Medical University Hospital

Second Surgery Department, Affiliated Hospital of Wakayama Prefectural Medical University

Department of Surgery, Osaka Minami Hospital

Medical corporation Yoshihidekai Takaishi Fujii Hospital general medical department director (Osaka), etc.

2015  Established Hiroi clinic

Director Hiroi has the experience of treating more than 150 terminal cancer patients, and has accumulated rich knowledge and experience in clinical practice. Use this knowledge and experience to provide effective methods for terminal cancer patients and help as many people as possible "beat cancer".

Clinic address

〒663-8113 22-22

Koshienguchi 4-chome, Nishinomiya City, Hyogo Prefecture

If you have any questions, please feel free to contact us through any of the methods below.

Name: *

Mailbox: *

Telephone: *




TW contact only: +886-90-5563-717

JP For emergency contact: +81-80-4276-3930


​JP Tel / Fax:  +81-92 -984-3200



LINE@ ID: @medicalsupporter


LINE & WeChat & Skype: medicalsupporter

  • Facebook
  • Instagram
bottom of page